Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.27 USD
Change Today +0.0078 / 3.00%
Volume 2.8K
TPI On Other Exchanges
As of 6:40 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

tianyin pharmaceutical co in (TPI) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/5/15 - $0.78
52 Week Low
08/24/15 - $0.21
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

tianyin pharmaceutical co in (TPI) Related Businessweek News

No Related Businessweek News Found

tianyin pharmaceutical co in (TPI) Details

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company, develops, manufactures, markets, and sells patented biopharmaceutical medicines, branded generics, modernized traditional Chinese medicines, and active pharmaceutical ingredients in the People’s Republic of China. It offers a portfolio of 58 products for use in the therapeutic areas of internal medicines, gynecology, hepatology, otolaryngology, urology, neurology, gastroenterology, and orthopedics. The company markets its products through regional distributors, as well as directly to the hospitals, clinics, and pharmacies. Tianyin Pharmaceutical Co., Inc. was founded in 1994 and is headquartered in Chengdu, the People’s Republic of China.

1,000 Employees
Last Reported Date: 12/9/14
Founded in 1994

tianyin pharmaceutical co in (TPI) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $100.0K
Chief Operating Officer, Chief Advisor of Sal...
Total Annual Compensation: $80.0K
Chief Technology Officer
Total Annual Compensation: $80.0K
Vice President of Marketing & Sales
Total Annual Compensation: $80.0K
Compensation as of Fiscal Year 2014.

tianyin pharmaceutical co in (TPI) Key Developments

Tianyin Pharmaceutical Inc. Receives Non-Compliance Notice From NYSE

Tianyin Pharmaceutical Inc. provided updates regarding the notice it received on May 21, 2015 from the NYSE MKT LLC indicating that the company was below certain of the Exchange's continued listing standards, as set forth in Sections 134 and 1101 of the NYSE MKT Company Guide, due to the delay in filing of its Quarterly Report on Form 10-Q for the period ended March 31, 2015 (Form 10-Q). On July 24, 2015, the company received another notice from the Exchange in connection with the filing of the Form 10-Q that the company continued to be not in compliance with Sections 134 and 1101 of the NYSE MKT Company Guide and that its listing is being continued pursuant to an extension. Under NYSE MKT rules, until the company files the Form 10-Q, its common stock will continue to be subject to the '.LF' indicator to signify its late filing status and will remain on the list of NYSE MKT noncompliant issuers. In order to maintain its listing, the company must regain compliance with Sections 134 and 1101 of the NYSE MKT Company Guide by August 21, 2015. Failure to regain compliance within the given timeframe will likely result in the Exchange Staff indicating delisting procedures pursuant to Section 1009 of the Company Guide. Currently the company is working diligently with the auditor to compile and disseminate the information required to be included in the Form 10-Q, as well as the required review of the company's financial information. The company expects to file the Form 10-Q as soon as possible and before the deadline set by the Exchange.

Tianyin Pharmaceutical Co., Inc. Announces Further Updates on Joint Venture with Buchang Pharmaceutical Co., Ltd

Tianyin Pharmaceutical Co., Inc. further updated that the discussions between Chengdu Tianyin and Buchang Pharma have further developed towards increasing percentage of ownership by Buchang Pharma in the Tianyin-Buchang Alliance joint venture. The total registered capital for the joint venture is RMB 200 million (approximately $33 million), of which the TPI's subsidiary Chengdu Tianyin Pharmaceutical Co., Ltd. owns 95% and Buchang Pharma owns 5%.

Buchang Pharma In Talks to Increase Stake in Tianyin-Buchang Alliance

Xianyang Buchang Pharmaceutical Co., Ltd. is in advanced stage of the discussions to significantly increase its stake in the Tianyin-Buchang Alliance joint venture from Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI). The integration of sales network of TPI-Buchang Pharma platform is currently ongoing.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TPI:US $0.27 USD +0.0078

TPI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ImmunoCellular Therapeutics Ltd $0.44 USD +0.0297
Northwest Biotherapeutics Inc $7.70 USD -0.41
Opexa Therapeutics Inc $0.42 USD +0.0354
StemCells Inc $0.41 USD +0.01
View Industry Companies

Industry Analysis


Industry Average

Valuation TPI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.3x
Price/Book 0.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TIANYIN PHARMACEUTICAL CO IN, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at